The research, led by Ruizhe Huang, Zhiyi Liu and Yawei Zhao under the correspondence of Siyu Chen at the Department of Medical Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, was built on a strikingly broad computational foundation. The team integrated seven single-cell RNA-sequencing cohorts, two spatial transcriptomic cohorts, bulk RNA sequencing linked to patient survival data, CRISPR-based gene essentiality screens, and three independent immunotherapy cohorts. Rather than relying on any single analytical method, the investigators assembled a machine learning framework in which different algorithms handled different parts of the problem, each feeding its output into the next stage of analysis.

The first step involved unsupervised consensus non-negative matrix factorization, a mathematical technique that decomposes gene expression data into coherent transcriptional programs without any prior labeling. Applied to malignant cells across the cohorts, this approach resolved four distinct malignant meta-programs. One of these, designated MP3, carried a mixed mesenchymal and interferon signaling signature, suggesting tumor cells that had partially undergone epithelial–mesenchymal transition while simultaneously mounting inflammatory responses. Crucially, the researchers found that MP3 carried prognostic information only in the context of the other three programs. When considered in isolation, its signal was misleading; when modeled jointly, patients with higher MP3 activity relative to the other programs fared significantly worse, with a hazard ratio of 1.43 per standard deviation and a p-value of 0.0045.

That context-dependence led the team to construct a composite score, essentially the difference between standardized MP3 activity and the activity of a fourth program, MP4, which resembled healthy alveolar cells and was independently protective. This single composite metric, z(MP3) minus z(MP4), proved prognostic on its own, with a hazard ratio of 1.40 and a p-value of 3.4 multiplied by ten to the negative sixth power. The reciprocal balance between an aggressive, plastic mesenchymal state and a differentiated, alveolar-like state thus encoded clinically meaningful information that neither program revealed alone. It is a technical but important lesson: in tumors defined by cellular plasticity, the relative composition of transcriptional states, not the abundance of any one state, appears to determine patient outcomes.

Having established the malignant programs, the researchers turned to the immune microenvironment and deployed deep generative models to interrogate neutrophils. Using scVI and its supervised extension scANVI, probabilistic models designed to denoise single-cell data and transfer cell type labels across datasets, the team resolved distinct neutrophil states within the tumor microenvironment. What emerged was an OSM-primed neutrophil axis. OSM, or oncostatin M, is an inflammatory cytokine, and neutrophils primed with it appeared to participate in a signaling circuit alongside SPP1-positive macrophages, the very cell population that had dominated prior studies of mesenchymal transition in this cancer. The two cell types formed what the authors describe as a partitioned dual circuit, with neutrophils and macrophages occupying complementary roles in sustaining the mesenchymal niche.

What made this finding particularly compelling was its spatial validation. Single-cell data strips away geography, telling researchers which cells exist but not where they sit within the tumor. To recover that geometry, the team applied cell2location, a probabilistic deep learning method for spatial deconvolution that estimates which cell types and states occupy each spot in a spatial transcriptomics slide. They coupled this with random forest multi-view modeling to map communication fluxes between cell populations. The results showed that OSM signaling flux was directed primarily toward macrophages and fibroblasts rather than toward the malignant cells themselves, which means that any influence of the neutrophil circuit on tumor cells is likely indirect, mediated through the stromal and macrophage compartments. The two-compartment niche, pairing OSM-primed neutrophils with their macrophage and fibroblast partners, was reproducible across both spatial cohorts, strengthening confidence that it reflects genuine tumor architecture rather than computational artifact.

The final and perhaps most ambitious stage of the pipeline used Geneformer, a transformer-based single-cell foundation model pretrained on large corpora of gene expression data, to perform in silico gene deletion perturbations. In effect, the model simulates what happens to a cell’s transcriptional state when a particular gene is removed, allowing researchers to computationally screen candidate dependencies across the three coupled state transitions identified in the study: from alveolar-like to mesenchymal malignant states, and through the associated neutrophil and macrophage circuits. The screen converged on SEC61G, a gene encoding a component of the SEC61 translocon, the protein channel in the endoplasmic reticulum membrane through which secreted and membrane proteins pass as they are synthesized. Because mesenchymal tumor cells and inflammatory immune cells both rely heavily on protein secretion, a translocon dependency is biologically plausible.

The authors are notably careful about how they frame this nomination. SEC61G already had independent published support in lung adenocarcinoma, so the team treats it as a positive control re-derived de novo rather than a wholly new drug target. What they report as genuinely new is that SEC61G’s prognostic signal is independent of 7p11.2 copy number, the chromosomal region in which the gene resides and a region frequently amplified in this cancer. In other words, the poor outcomes associated with high SEC61G expression are not simply a reflection of having more copies of the gene, hinting at regulatory or functional dependencies that copy number analysis alone would miss. The overall survival hazard ratio for SEC61G was 1.64 with a p-value of 1.3 multiplied by ten to the negative sixth, and the gene showed higher expression in immunotherapy non-responders in two of the three checkpoint inhibitor cohorts examined, reaching statistical significance in one.

What elevates this study above a typical bioinformatics exercise is its insistence on orthogonal validation. The four-endpoint validation cascade required convergent evidence from survival analysis, immunotherapy response data, CRISPR essentiality screens, and the perturbation modeling itself before any candidate dependency was accepted. This design directly addresses one of the most persistent criticisms of single-cell oncology research: that computational nominations of drug targets often evaporate under experimental scrutiny. By demanding agreement across data types that share no common analytical machinery, the framework filters out candidates whose signals are artifacts of any single method or dataset. The result is a shorter but far more defensible list of candidate targets than a typical computational screen would produce.

The broader significance lies in the generalizability of the approach. The authors explicitly position their strategy, foundation model perturbation followed by multi-endpoint orthogonal validation, as a reusable template for nominating therapeutic targets in plasticity-driven solid tumors, a category that includes many of the hardest cancers to treat. As foundation models like Geneformer mature and spatial transcriptomic datasets accumulate, pipelines of this kind could compress the path from observational single-cell atlases to testable therapeutic hypotheses. For lung adenocarcinoma patients, the immediate deliverables are a newly mapped neutrophil-associated mesenchymal niche that reframes how the tumor microenvironment sustains aggressive cell states, and a candidate translocon dependency whose vulnerability can now be pursued with experimental tools. The work was funded by the National Natural Science Foundation of China and the Shanghai Committee of Science and Technology, and relied exclusively on publicly available, de-identified human data, meaning that its findings can be independently reanalyzed and challenged by any laboratory with computational resources and internet access.

Subject of Research: Deep learning integration of single-cell and spatial transcriptomics to map a neutrophil-associated mesenchymal niche and identify candidate tumor dependencies in lung adenocarcinoma.

Article Title: Deep learning integration of single-cell and spatial transcriptomics reveals a neutrophil-associated mesenchymal niche and a candidate translocon dependency in lung adenocarcinoma

Article References: Deep learning integration of single-cell and spatial transcriptomics reveals a neutrophil-associated mesenchymal niche and a candidate translocon dependency in lung adenocarcinoma. (n.d.). https://doi.org/10.1007/s00262-026-04560-3

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04560-3

Keywords: lung adenocarcinoma, single-cell RNA sequencing, spatial transcriptomics, tumor-associated neutrophils, epithelial–mesenchymal transition, SEC61G, deep learning, tumor microenvironment, Geneformer, immunotherapy response, OSM signaling, cancer prognosis